You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 64 No. 9, September 2007 TABLE OF CONTENTS
  Archives
  •  Online Features
  Correction
 This Article
 •PDF of this Correction
 •Original article
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Bipolar Disorder
 •Depression
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Errors in Funding/Support, Financial Disclosure, Tables, and Text in: Lifetime and 12-Month Prevalence of Bipolar Spectrum Disorder in the National Comorbidity Survey Replication

Arch Gen Psychiatry. 2007;64(9):1039.

Errors in Funding/Support, Financial Disclosure, Tables, and Text. In the Original Article by Merikangas et al titled "Lifetime and 12-Month Prevalence of Bipolar Spectrum Disorder in the National Comorbidity Survey Replication," published in the May issue (2007;64[5]:543-552), there were several errors.

First, the following sentence in the Funding/Support section was incorrect: "The preparation of this article was supported by AstraZeneca." AstraZeneca did not provide any financial or scientific support for this study.

Second, in addition to the financial disclosure of Dr Hirschfeld, that section should have contained the following: "Dr Akiskal is a consultant to or serves on the advisory board of Abbott International, GlaxoSmithKline, and Sanofi-Aventis. Dr Angst is a consultant to or serves on the advisory board of AstraZeneca and Eli Lilly and Company. Mr Greenberg is a consultant to or serves on the advisory board of AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, Forest Laboratories, Ortho Biotech, and Sanofi-Aventis. Dr Kessler is a consultant to or serves on the advisory board of AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, Sanofi-Aventis, and Wyeth-Ayerst.

Third, Table 1 and Tables 3 through 6 were labeled incorrectly with regard to SD and SE. In Table 1, the mention of SD should have read SE. In Tables 3 through 6, the mentions of SE should have read SD. A corrected version of Table 1 with SDs is available at http://www.hcp.med.harvard.edu/ncs/ftpdir/PA377%20erratum.pdf.

Fourth, the reference to inappropriate pharmacological treatment of bipolar disorder should have been restricted to bipolar disorders I and II and not included subthreshold bipolar disorder.

Errors 3 and 4 were pointed out by Bernard Carroll, MD.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2007 American Medical Association. All Rights Reserved.